Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 569

1.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS.

JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130.

PMID:
29318276
2.

Distinguishing between CISNET model results versus CISNET models.

Berry DA, de Koning HJ, Lee SJ, Mandelblatt JS, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A; CISNET Breast Working Group Principal Investigators.

Cancer. 2017 Dec 26. doi: 10.1002/cncr.31150. [Epub ahead of print] No abstract available.

PMID:
29278430
3.

Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.

de Carvalho TM, Heijnsdijk EAM, de Koning HJ.

Cancer. 2018 Feb 1;124(3):507-513. doi: 10.1002/cncr.31141. Epub 2017 Dec 12.

PMID:
29231973
4.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R.

Cancer. 2017 Dec 6. doi: 10.1002/cncr.31178. [Epub ahead of print]

PMID:
29211316
5.

European position statement on lung cancer screening.

Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel CP, Bastarrika G, Sverzellati N, Mascalchi M, Delorme S, Baldwin DR, Callister ME, Becker N, Heuvelmans MA, Rzyman W, Infante MV, Pastorino U, Pedersen JH, Paci E, Duffy SW, de Koning H, Field JK.

Lancet Oncol. 2017 Dec;18(12):e754-e766. doi: 10.1016/S1470-2045(17)30861-6. Review.

PMID:
29208441
6.

Re: Think before you leap.

Han SS, Ten Haaf K, Hazelton WD, Jeon J, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK.

Int J Cancer. 2017 Dec 1. doi: 10.1002/ijc.31183. [Epub ahead of print] No abstract available.

PMID:
29194597
7.

Disagreement of diameter and volume measurements for pulmonary nodule size estimation in CT lung cancer screening.

Heuvelmans MA, Walter JE, Vliegenthart R, van Ooijen PMA, De Bock GH, de Koning HJ, Oudkerk M.

Thorax. 2017 Oct 22. pii: thoraxjnl-2017-210770. doi: 10.1136/thoraxjnl-2017-210770. [Epub ahead of print]

PMID:
29056601
8.

Lung cancer screening and its continuous risk assessment.

de Koning HJ.

Lancet Oncol. 2017 Nov;18(11):1434-1436. doi: 10.1016/S1470-2045(17)30730-1. Epub 2017 Oct 18. No abstract available.

PMID:
29055737
9.

Summary statement on screening for prostate cancer in Europe.

Heijnsdijk EAM, Bangma CH, Borràs JM, de Carvalho TM, Castells X, Eklund M, Espinàs JA, Graefen M, Grönberg H, Lansdorp-Vogelaar I, Leeuwen PJV, Nelen V, Recker F, Roobol MJ, Vandenbulcke P, de Koning HJ.

Int J Cancer. 2018 Feb 15;142(4):741-746. doi: 10.1002/ijc.31102. Epub 2017 Oct 25.

PMID:
29023685
10.

Influence of lung nodule margin on volume- and diameter-based reader variability in CT lung cancer screening.

Han D, Heuvelmans MA, Vliegenthart R, Rook M, Dorrius MD, de Jonge GJ, Walter JE, van Ooijen PMA, de Koning HJ, Oudkerk M.

Br J Radiol. 2017 Nov 8:20170405. doi: 10.1259/bjr.20170405. [Epub ahead of print]

PMID:
28972803
11.

Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis.

Phi XA, Houssami N, Hooning MJ, Riedl CC, Leach MO, Sardanelli F, Warner E, Trop I, Saadatmand S, Tilanus-Linthorst MMA, Helbich TH, van den Heuvel ER, de Koning HJ, Obdeijn IM, de Bock GH.

Eur J Cancer. 2017 Nov;85:31-38. doi: 10.1016/j.ejca.2017.07.055. Review.

PMID:
28886475
12.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R.

Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.

PMID:
28869989
13.

Coronary Artery Calcium Imaging in the ROBINSCA Trial: Rationale, Design, and Technical Background.

Vonder M, van der Aalst CM, Vliegenthart R, van Ooijen PMA, Kuijpers D, Gratama JW, de Koning HJ, Oudkerk M.

Acad Radiol. 2018 Jan;25(1):118-128. doi: 10.1016/j.acra.2017.07.010. Epub 2017 Aug 23. Review.

PMID:
28843465
14.

Uniform and blinded cause of death verification of the NELSON lung cancer screening participants.

Yousaf-Khan AU, van der Aalst CM, Aerts JGJV, den Bakker MA, de Koning HJ.

Lung Cancer. 2017 Sep;111:131-134. doi: 10.1016/j.lungcan.2017.07.018. Epub 2017 Jul 22.

PMID:
28838383
15.

Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model.

Idigoras I, Arrospide A, Portillo I, Arana-Arri E, Martínez-Indart L, Mar J, de Koning HJ, Lastra R, Soto-Gordoa M, van der Meulen M, Lansdorp-Vogelaar I.

BMC Public Health. 2017 Aug 1;18(1):78. doi: 10.1186/s12889-017-4639-3. Erratum in: BMC Public Health. 2017 Sep 22;17 (1):736.

16.

The effect of omitting an early population-based vision screen in the Netherlands: A micro-simulation model approach.

Sloot F, Heijnsdijk E, Groenewoud JH, Goudsmit F, Steyerberg EW, de Koning HJ, Simonsz HJ.

J Med Screen. 2017 Sep;24(3):120-126. doi: 10.1177/0969141316670422. Epub 2016 Oct 22.

PMID:
28756763
17.

Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.

Lansdorp-Vogelaar I, Goede SL, Bosch LJW, Melotte V, Carvalho B, van Engeland M, Meijer GA, de Koning HJ, van Ballegooijen M.

Clin Gastroenterol Hepatol. 2017 Jul 18. pii: S1542-3565(17)30848-0. doi: 10.1016/j.cgh.2017.07.011. [Epub ahead of print]

PMID:
28733262
18.

Authors' reply to: "Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands".

Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, de Koning HJ.

Int J Cancer. 2017 Oct 15;141(8):1709-1710. doi: 10.1002/ijc.30873. Epub 2017 Jul 21. No abstract available.

PMID:
28681483
19.

Functional and structural analysis of AT-specific minor groove binders that disrupt DNA-protein interactions and cause disintegration of the Trypanosoma brucei kinetoplast.

Millan CR, Acosta-Reyes FJ, Lagartera L, Ebiloma GU, Lemgruber L, Nué Martínez JJ, Saperas N, Dardonville C, de Koning HP, Campos JL.

Nucleic Acids Res. 2017 Aug 21;45(14):8378-8391. doi: 10.1093/nar/gkx521.

20.

Quantification of growth patterns of screen-detected lung cancers: The NELSON study.

Heuvelmans MA, Vliegenthart R, de Koning HJ, Groen HJM, van Putten MJAM, Yousaf-Khan U, Weenink C, Nackaerts K, de Jong PA, Oudkerk M.

Lung Cancer. 2017 Jun;108:48-54. doi: 10.1016/j.lungcan.2017.02.021. Epub 2017 Mar 1.

Supplemental Content

Loading ...
Support Center